arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by...
DESCRIPTION
BCT-100 arginine depletion reduces the number of viable AML blasts in vitro and in vivo. Francis Mussai et al. Blood 2015;125: ©2015 by American Society of HematologyTRANSCRIPT
![Page 1: Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,](https://reader036.vdocument.in/reader036/viewer/2022081605/5a4d1bac7f8b9ab0599cb2c8/html5/thumbnails/1.jpg)
Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target
by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones, Tracey Perry, Andrew Beggs, Elena Odintsova, Justin Loke, Guy Pratt, Kin Pong U, Anthony Lo,
Margaret Ng, Pamela Kearns, Paul Cheng, and Carmela De Santo
BloodVolume 125(15):2386-2396
April 9, 2015
©2015 by American Society of Hematology
![Page 2: Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,](https://reader036.vdocument.in/reader036/viewer/2022081605/5a4d1bac7f8b9ab0599cb2c8/html5/thumbnails/2.jpg)
AML blasts are auxotrophic for arginine.
Francis Mussai et al. Blood 2015;125:2386-2396
©2015 by American Society of Hematology
![Page 3: Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,](https://reader036.vdocument.in/reader036/viewer/2022081605/5a4d1bac7f8b9ab0599cb2c8/html5/thumbnails/3.jpg)
BCT-100 arginine depletion reduces the number of viable AML blasts in vitro and in vivo.
Francis Mussai et al. Blood 2015;125:2386-2396
©2015 by American Society of Hematology
![Page 4: Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,](https://reader036.vdocument.in/reader036/viewer/2022081605/5a4d1bac7f8b9ab0599cb2c8/html5/thumbnails/4.jpg)
BCT-100 is cytotoxic against primary blasts from patients.
Francis Mussai et al. Blood 2015;125:2386-2396
©2015 by American Society of Hematology
![Page 5: Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,](https://reader036.vdocument.in/reader036/viewer/2022081605/5a4d1bac7f8b9ab0599cb2c8/html5/thumbnails/5.jpg)
BCT-100 depletes arginine intracellularly.
Francis Mussai et al. Blood 2015;125:2386-2396
©2015 by American Society of Hematology
![Page 6: Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,](https://reader036.vdocument.in/reader036/viewer/2022081605/5a4d1bac7f8b9ab0599cb2c8/html5/thumbnails/6.jpg)
BCT-100 halts proliferation and cell cycle arrest.
Francis Mussai et al. Blood 2015;125:2386-2396
©2015 by American Society of Hematology
![Page 7: Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target by Francis Mussai, Sharon Egan, Joseph Higginbotham-Jones,](https://reader036.vdocument.in/reader036/viewer/2022081605/5a4d1bac7f8b9ab0599cb2c8/html5/thumbnails/7.jpg)
BCT-100 induced cell cycle arrest leads to necrotic cell death.
Francis Mussai et al. Blood 2015;125:2386-2396
©2015 by American Society of Hematology